Top Stocks
Dividend Investing
ETFs
Stock Comparison
About Us
Working with TipRanks
Follow Us
Unicycive Therapeutics (UNCY)
NASDAQ:UNCY
Unicycive Therapeutics (UNCY) Stock Price & Analysis
27 Followers
UNCY Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$0.40 - $2.87
Previous Close$1.91
Volume432.63K
Average Volume (3M)6.08M
Market Cap
$28.82M
Enterprise Value$22.00M
Total Cash (Recent Filing)$7.01M
Total Debt (Recent Filing)$194.00K
Price to Earnings (P/E)-1.9
Beta-2.88
Next Earnings
Mar 30, 2023EPS Estimate
-$0.26Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.03
Shares Outstanding15,088,670
10 Day Avg. Volume173,913
30 Day Avg. Volume6,076,585
Standard Deviation0.14
R-Squared0.37
Alpha-0.07
Financial Highlights & Ratios
Price to Book (P/B)1.73
Price to Sales (P/S)8.41
Price to Cash Flow (P/CF)N/A
P/FCF Ratio-0.80
Enterprise Value/Market CapN/A
Enterprise Value/Revenue23.14
Enterprise Value/Gross Profit10.00T>
Enterprise Value/Ebitda-1.43
Forecast
1Y Price Target
$8.00Price Target Upside318.85% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
Unicycive Therapeutics News
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Product Monthly Users
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
UNCY FAQ
What was Unicycive Therapeutics’s price range in the past 12 months?
Unicycive Therapeutics lowest stock price was $0.40 and its highest was $2.87 in the past 12 months.
What is Unicycive Therapeutics’s market cap?
Currently, no data Available
When is Unicycive Therapeutics’s upcoming earnings report date?
Unicycive Therapeutics’s upcoming earnings report date is Mar 30, 2023 which is in 5 days.
How were Unicycive Therapeutics’s earnings last quarter?
Unicycive Therapeutics released its earnings results on Nov 14, 2022. The company reported -$0.37 earnings per share for the quarter, missing the consensus estimate of -$0.28 by -$0.09.
Is Unicycive Therapeutics overvalued?
According to Wall Street analysts Unicycive Therapeutics’s price is currently Undervalued.
Does Unicycive Therapeutics pay dividends?
Unicycive Therapeutics does not currently pay dividends.
What is Unicycive Therapeutics’s EPS estimate?
Unicycive Therapeutics’s EPS estimate is -$0.26.
How many shares outstanding does Unicycive Therapeutics have?
Unicycive Therapeutics has 15,088,670 shares outstanding.
What happened to Unicycive Therapeutics’s price movement after its last earnings report?
Unicycive Therapeutics reported an EPS of -$0.37 in its last earnings report, missing expectations of -$0.28. Following the earnings report the stock price went down -5.556%.
Which hedge fund is a major shareholder of Unicycive Therapeutics?
Currently, no hedge funds are holding shares in UNCY
---
Unicycive Therapeutics Stock Smart Score
Not Ranked
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$8.00 (318.85% Upside)
$8.00 (318.85% Upside)
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
45.80%
12-Months-Change
Fundamentals
Return on Equity
-131.08%
Trailing 12-Months
Asset Growth
-48.55%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Unicycive Therapeutics
Unicycive Therapeutics Inc is a biotechnology company dedicated towards developing treatments for certain medical conditions. It is focusing on kidney diseases. The company's lead drug, Renazorb, is a novel phosphate binding agent being developed for the treatment of hyperphosphatemia. Unicycive's other drug, UNI-494, is a new chemical entity with issued composition of matter patent protection in late preclinical development for the treatment of acute kidney injury.
---
Top 5 ETFs holding UNCY
Currently, no data available
Please return soon. This page is being updated.
Up to five ETFs with an Outperform Smart Score that hold UNCY. The ETFs are listed according to market value of UNCY within the ETF
---
Theriva Biologics
―
Silo Pharma
―
NexImmune
―
Lixte Biotechnology Holdings
―
Innovation Pharmaceuticals
―
---